Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2014-07-23 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 40.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed quarterly financial data including consolidated cash flow statements, cash reconciliation, and notes on financing activities. It is a quarterly report with substantive financial data and analysis for the quarter ended 30 June 2014. The document is over 7,000 characters, indicating it is a full report rather than a brief announcement. The content aligns with a comprehensive interim or quarterly financial report rather than a simple earnings release or regulatory filing. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2014
2014-07-23 English
BIT225 Reverses HIV-Induced Impairment of the Immune System 3 pages 771.7KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Biotron Limited about clinical trial results for their drug BIT225 targeting HIV infection. It includes extensive clinical data, study design, patient demographics, antiviral efficacy results, immune activation markers, and conclusions about the drug's effects. The content is scientific and data-rich, focusing on trial outcomes and drug efficacy rather than financial results or regulatory compliance. There is no indication that this is a financial report, earnings release, or regulatory filing. It is a clinical trial results announcement, which typically falls under general regulatory announcements or disclosures. Given the detailed nature and the absence of financial statements or governance information, the best fit is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories. The document is about clinical trial results and drug efficacy, not about financial performance or corporate governance changes.
2014-07-22 English
Response to ASX price query 3 pages 82.5KB
Regulatory Filings Classification · 95% confidence The document is a letter from Biotron Limited to ASX Compliance Pty Limited responding to a price query regarding an increase in the company's share price and trading volume. It references ASX Listing Rules, specifically Listing Rule 3.1 about continuous disclosure obligations. The document is a compliance response to a regulatory inquiry rather than a financial report or announcement of financial results. It does not contain financial statements, earnings data, or detailed management discussion. It is a regulatory filing responding to a market price query, which fits the category of Regulatory Filings (RNS). The document length (7241 characters) and content confirm it is not a brief announcement or a full report but a regulatory compliance letter.
2014-06-05 English
Presentation to Investors 26 pages 1.4MB
Investor Presentation Classification · 95% confidence The document is a detailed PowerPoint presentation delivered by the CEO of Biotron Limited to investors, as explicitly stated in the cover letter. It contains extensive information about the company's clinical trials, drug development pipeline, market analysis, and financial metrics. The content is forward-looking and strategic, focusing on product profiles, clinical trial phases, and market positioning rather than formal financial statements or regulatory disclosures. There is no indication that this is an official annual or quarterly report, audit report, or earnings release. The document is a presentation aimed at investors, providing detailed insights into the company's business and financial outlook. Therefore, the appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2014-05-26 English
BIT225 HCV Trial Update - Thailand 2 pages 42.6KB
Regulatory Filings Classification · 95% confidence The document is a company announcement dated 23 May 2014 from Biotron Limited providing an update on the status of a Phase 2 clinical trial for their drug BIT225 targeting Hepatitis C virus (HCV). It discusses trial progress, locations, patient enrollment, and expected timelines for preliminary data. There are no financial statements, regulatory filings, or detailed financial results presented. The document is short (3886 characters) and serves as a progress update on a clinical trial rather than a financial or regulatory report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an operational update related to clinical trial progress, which is typically classified under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2014-05-22 English
Appendix 4C - quarterly 6 pages 67.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and references ASX Listing Rule 4.7B. It contains detailed quarterly cash flow statements, including operating, investing, and financing activities, as well as reconciliation of cash and compliance statements. The document covers the quarter ended 31 March 2014 and provides substantive financial data and analysis for that period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive financial data. The document is not merely an announcement or certification but includes detailed financial information. Therefore, the correct classification is IR with high confidence. Q3 2014
2014-04-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.